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Thomas Lotz1, Kirsten A McAuley2, J Geoffrey Chase1, Geoffrey M Shaw3 and Jim I Mann2
1Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand
2Edgar National Centre for Diabetes Research, Dunedin, New Zealand
3Dept of Intensive Care Medicine, Christchurch Hospital, Christchurch, New Zealand
1. Model validation on euglycemic clamp data [3]
b) Change in insulin sensitivity in intervention study by McAuley et al. [4]
a) Correlation clamp
ISI vs. model SIr=0.97
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Type 2 Diabetes affects more than 230 million people worldwide and is responsible for 
3.5 million deaths annually [1].
About 215 000 New Zealanders are estimated to have type 2 Diabetes and an equal 
number are insulin resistant, prior to developing the disease [2].
Costs for the NZ public health system: $540 million in 2006, expected to rise over $1.8 
billion by 2021 [2].
Early diagnosis of insulin resistance can reduce the burden of further complications and 
save lives and cost. Current diagnostic methods are too expensive and complicated to be 
useful in widespread population screening (euglycaemic clamp, IVGTT), or not accurate 
enough to give more than a high/low result (HOMA, OGTT).
Introduction
Insulin resistance rises up to 10 years prior to diagnosis
The test is designed to measure the same metabolic effect 
as the gold standard euglycaemic hyperinsulinaemic
clamp.
Design goals:
Simple, low intensity, high accuracy, low cost, physiological 
dosing
The protocol:
1.Low dose bolus of glucose (10g) and insulin (1U)
Reduce endogenous regulatory effects
Improve clinical practicability and safety
2. 30 min timed sampling of glucose, insulin and C-peptide
3. Fit metabolic models
Only transient data from 10 - 30 minutes post bolus
Identification requires only few samples
4. Determine insulin sensitivity from model parameter SI5. Determine b-cell function from C-peptide data
Test design
Accuracy vs. Intensity
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Normal Glucose Tolerant (NGT)
•High insulin sensitivity (11.7 x 10-4 mU/l/min)
•Healthy 1st phase insulin response
•Rapid decay of glucose concentration
Impaired Fasting Glucose (IFG)
•Low insulin sensitivity (3.2 x 10-4 mU/l/min)
•Impaired 1st phase insulin response
•Elevated insulin secretion throughout
•Slow decay of glucose concentration
Type 2 diabetes
•Low insulin sensitivity (6.7 x 10-4 mU/l/min)
•Insignificant 1st phase insulin response
•Significant b-cell damage
•Elevated glucose concentrationsProvide complete diagnostic information about:
•Insulin sensitivity
•β-cell function
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1.Glucose + 
insulin bolus
2. 30 min timed 
blood sampling
3. Fit metabolic 
models
4. Determine 
insulin sensitivity
5. Determine 
b-cell 
function
•Basal secretion
•1st phase 
secretion
2. Clinical Pilot study: 
17 subjects, 43 tests
Part 1: Effect of dose on outcome
• Low dose: 5g glucose / 0.5U insulin
• Medium dose: 10g glucose / 1U insulin
• High dose: 20g glucose / 2U insulin
Difference not statistically 
significant (P=0.5, P=0.52)
Part 2: Repeatability
• Same dose on same individual on a 
different day
Error 6.0% (MSD 4.9)
Range 1.7% - 24.7%
Test outcome on 3 
exemplary subjects 
spanning the range 
from NGT to Type 2 
Diabetes
